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ABSTRACT
Introduction: Locally advanced cervical cancer (LACC) (International Federation of Gynecology and 
Obstetrics (FIGO) 2009/2018 – stages IB2-IVA/IB3-IVA, respectively) is treated using a multimodal 
approach that includes chemoradiotherapy followed by brachytherapy.
Areas covered: This review provides an overview of the progress made over the past decade in the 
treatment of LACC. Prognostic factors, FIGO classification and the role of imaging staging will be 
discussed. Efficacy of external-beam radiotherapy, brachytherapy and chemotherapy will be detailed. 
Indications for para-aortic staging lymphadenectomy and adjuvant hysterectomy, as well as follow-up 
and special population, will be covered.
Expert opinion: The initial workup is one of the most crucial steps in the optimal care of patients, 
which should be realized by a multidisciplinary expert team. With the implementation of modern 
conformal radiotherapy techniques, the local control rate has been optimized. Nevertheless, 40% of 
patients experience recurrence with distant metastasis and a dismal prognosis. Currently, a clear benefit 
of neo- and adjuvant chemotherapy has not been established. The future likely involves (1) improved 
selection of patients for whom treatment intensification is justified, (2) a combination of new drugs with 
chemoradiation that are currently being tested in trials, and (3) the development of tailored treatment 
based on molecular characteristics.
ARTICLE HISTORY
Received 1 September 2020  







locally advanced cervical 
cancer; lymphadenectomy
1. Introduction
According to GLOBOCAN 2018, cervical cancer (CC) is the 
fourth most common cancer in women worldwide after 
breast, colorectal and lung cancers and is the second most 
common in developing countries, where more than 85% of 
these cases occur. Worldwide, an estimated 569,847 new cases 
and 311,365 deaths are recorded, although incidence and 
mortality vary widely among countries [1,2].
Several risk factors are recognized, including sexually trans-
mitted diseases (primarily human papillomavirus infection 
(HPV), other human immunodeficiencies and herpes simplex 
virus), reproductive and sexual factors (multiple sexual part-
ners, early age at first sexual intercourse and at first delivery, 
and oral contraceptive pills), and behavioral factors (e.g. smok-
ing) [3].
Persistent infection with HPV, a sexually transmitted deox-
yribonucleic acid (DNA) virus, is detected in 99% of CC cases. 
Although the majority of HPV infections are transitory, HPV 
persists in 10% of cases, leading to the development of a pre- 
or invasive lesion 15 to 20 years after the initial infection. 
Primary prevention has been realized through HPV vaccination 
and screening via Papanicolaou (Pap) cytological test or HPV 
DNA testing [4–7].
Most frequently reported symptoms are vaginal bleeding, 
dyspareunia or pain due to local muscular or nervous 
infiltration. However, CC may be asymptomatic when it is 
detected at an early stage during screening.
Squamous cell carcinoma (SCC), adenocarcinoma (ADC), 
and adenosquamous carcinoma (ADSC) are the three most 
common histological subtypes, accounting for 70%, 25% and 
5% of cases, respectively. In contrast to SCC, which has experi-
enced a progressive decrease in incidence and mortality in 
recent decades, the incidence and mortality of ADC has 
increased during the same timeframe [8]. This evolution has 
been attributed to the Pap test and its ability to more effi-
ciently detect squamous, rather than glandular, neoplasia [9].
Overall survival (OS) at 5 years is approximatively 92%, 65% 
and 17% for early-stage, locally advanced and metastatic dis-
ease, respectively. The prognosis of patients with recurrent 
disease remains very poor, except in cases of local recurrence 
accessible to curative treatment.
Treatment strategy is dictated by the International 
Federation of Gynecology and Obstetrics (FIGO) classification. 
The majority of trials referenced in this review are based on 
the 2009 version; however, the updated FIGO 2018 classifica-
tion should now be used. Surgery is the principal treatment 
for early-stage disease (FIGO 2018 stages IA–IB2). For patients 
with locally advanced cervical cancer (LACC) (FIGO 2018 stages 
IB3–IVA), concomitant cisplatin-based chemoradiation (CCRT) 
followed by intrauterine brachytherapy (BT) is recommended 
by all international society guidelines [10].
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Although early-stage CC is often curable, 40 to 50% of 
patients are diagnosed at the locally advanced stage, which 
accounts for the principal cause of death. This review is dedi-
cated to discussing the most recent and multidisciplinary 
approaches for LACC.
2. Prognostic factors
LACC includes a heterogeneous group of diseases. In the era 
of personalized medicine, improved understanding and iden-
tification of the site-specific risk of relapse could provide an 
opportunity to tailor treatment and select patients who may 
benefit from new therapeutic strategies.
Various prognostic factors have been previously studied, 
including clinical (age, tumor size, nodal metastasis), morpho-
logical (tumor histology, HPV status), biological (anemia, leu-
kocytosis, lymphopenia, thrombocytosis at diagnosis) and 
radiological (initial [18F]FDG-PET/CT avidity) variables [11–14]. 
Also, HPV genotypes convey different prognoses [15,16].
Moreover, molecular biomarkers, such as cyclooxygenase-2, 
p53 and vascular endothelial growth factor (VEGF), have been 
studied, but their prognostic utility remains unclear [17–19]. In 
2017, the Cancer Genome Atlas Research Network identified new 
genomic and proteomic characteristics allowing subclassification 
of CC into the following categories: keratin-low squamous, keratin- 
high squamous, and adenocarcinoma-rich clusters. ERBB3, CASP8, 
HLA-A, SHKBP1 and TGFBR2 were identified as commonly mutated 
genes. They also reported amplification events in BCAR4, CD274 
and PDCD1LG2 genes, also known as PD-L1 and PD-L2, respec-
tively. Endometrial-like CC, especially in HPV-negative tumors, was 
discovered and characterized by mutations in KRAS, ARID1A and 
PTEN. Furthermore, more than 70% of CCs exhibit genomic altera-
tions in PI3K–MAPK or TGFβ signaling pathways [20]. In the near 
future, it is likely that potent biomarkers will contribute to the 
selection of patients who may benefit from treatment intensifica-
tion or, conversely, from treatment de-escalation.
3. International federation of gynecology and 
obstetrics (FIGO) classification
In 2018, FIGO updated their clinical classification by incorpor-
ating the use of imaging modalities and/or pathological find-
ings for determining the stage. Lateral extension 
measurement was removed from stage IA, and stage IB now 
includes three subgroups based on tumor size (in greatest 
dimension): stage IB1 (≤ 20 mm), stage IB2 (>20 mm to ≤ 
40 mm) and stage IB3 (>40 mm). A major change also 
included incorporation of lymph node (LN) status. If nodal 
status is positive, the stage is designated IIIC; in cases of only 
pelvic LN involvement, the stage is IIIC1. If para-aortic (PAo) 
LNs are positive, the stage is assigned IIIC2. Notations ‘r’ 
(imaging) and ‘p’ (pathology) indicate the method used to 
derive the stage [21,22].
Four recent large-scale retrospective cohort studies were 
conducted to validate this new classification [23–26]. They 
demonstrated good discrimination between the three groups 
in stage IB. Nodal status clearly impacts survival, with the risk 
of death nearly 1.5- and 2-fold greater for pelvic and PAo LN 
involvement, respectively. However, this effect varies greatly 
based on local T stage, leading to survival heterogeneity in 
patients with stage III subgroups [23].
4. Imaging workup
4.1. Local diagnostic
Gynecologic examination with colposcopy-guided biopsy and 
pelvic magnetic resonance imaging (MRI) are mandatory for 
primary tumor ‘T’ staging [27]. Thomeer et al. [28] published 
a meta-analysis comparing the diagnostic performances of clin-
ical examination and MRI in detecting parametrial invasion and 
advanced stage (FIGO stage ≥ IIB). For the evaluation of para-
metrial invasion/advanced disease, sensitivity was 40%/53% and 
84%/79% with clinical examination and MRI, respectively, clearly 
in favor of MRI [28]. Knoth et al. [29] demonstrated 27% of 
discrepancies between MRI and clinical gynecologic examina-
tion. With MRI, upstaging is more frequent than downstaging. 
Tumor size and parametrial infiltration seemed to be more 
correctly assessed with MRI. Vaginal and pelvic side wall infiltra-
tions were more precisely evaluated by gynecologic examina-
tion [29].
All these differences can have a major impact on the man-
agement of patients. Indeed, the accuracy of this staging is 
crucial in order to decide the best strategy for the patients: 
surgery or CCRT. A combination of informations gained from 
clinical examination (by experienced gynecologic oncologist) 
and MRI is probably the best approach.
Functional (dynamic contrast-enhanced or diffusion- 
weighted) MRI techniques can provide additional informations 
[30,31]. Transrectal or transvaginal ultrasound can also give 
detailed information when performed by ultrasound-trained 
gynecologists in experienced centers [10]. Cystoscopy or rec-
toscopy may be discussed to realize a biopsy if suspicious 
lesions in the bladder or rectum are detected on MRI.
4.2. Nodal diagnostic
Nodal staging is key as it influences both prognosis and treat-
ment planning. The performance of Positron emission tomo-
graphy/computed tomography using 18F-2ʹ-deoxy-2ʹ 
fluorodeoxyglucose ([18F]FDG-PET/CT) and chest/abdomen 
contrast-enhanced computed tomography for LN detection is 
clearly superior to standard MRI and tomography [32].
Article highlights
● Exhaustive, initial clinical, radiological, and even surgical workup is 
crucial
● Concomitant cisplatin-based conformal external-beam radiotherapy 
followed by image-guided adaptive brachytherapy is the current 
standard of care
● The exact benefit of neo- and adjuvant chemotherapy has not yet 
been established
● Various new therapeutic strategies are under evaluation in ongoing 
trials, such as antiangiogenesis agents and checkpoint immune 
receptor inhibitors
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PAo LN detection is a crucial point as it can result in upstaging 
and consecutive modification of treatment planning with 
extended-field radiotherapy (RT). The incidence of PAo LN 
involvement increases with tumor ‘T’ stage, ranging from 5% 
in patients with stage I disease to 23% in those with stage III. 
Nevertheless, the best strategy for detection of this PAo LN is 
a very controversial subject, regarding whether to implement 
a surgical versus radiological approach.
A meta-analysis based on 385 patients reported that 
pooled estimates for sensitivity and specificity of [18F]FDG- 
PET/CT in detecting PAo LN metastasis were 0.71 (95% CI 
0.54–0.83) and 0.97 (95% CI 0.93–0.98), respectively [33]. In 
addition, a 2013 Cochrane review found no evidence that 
surgical staging was beneficial [34].
Of note, Martinez et al. [35] and De Cuypere et al. [36] 
concluded that the risk of PAo LN metastasis in case of nega-
tive pelvic LN status on [18F]FDG-PET/CT is very low, so PAo 
lymphadenectomy does not seem justified in this subgroup of 
patients. In contrast, for patients with preoperative pelvic LN 
uptake on [18F]FDG-PET/CT, surgical staging led to treatment 
modification in more than 25% of cases and should therefore 
be performed [35,36].
Lymph node size can also modify the ability of [18F]FDG- 
PET/CT to correctly identify metastatic LNs. Metastases mea-
suring less than 5 mm have been identified in approximately 
half of patients with negative PAo LN on [18F]FDG-PET/CT [37].
Only two randomized control trials (RCTs) have been per-
formed to address the question of radiological-clinical or sur-
gical PAo LN evaluation. The Lai et al. [38] study was 
prematurely closed and limited by many methodological 
biases. UTERUS-11 study, with a median follow-up of 
90 months, compared the two methods of PAo LN staging in 
225 patients FIGO 2009 IIB-IVA with laparoscopic approach in 
> 95% of cases in the surgical arm. In fact, OS and progression- 
free survival (PFS) were not statistically different, whereas 
cancer-specific survival (CSS) favored the surgical 
approach. Moreover, surgical staging was safe and neither 
delayed CCRT nor increased complications [39]. The results 
of the Lymphadenectomy in Locally Advanced Cervical 
Cancer (LiLACS) phase III trial are pending, but this study is 
not currently recruiting [40].
4.3. Distant metastases
Initial [18F]FDG-PET/CT staging demonstrates 6 to 14% of cases 
with distant metastases with a high specificity (98%), positive 
predictive value (79%) and a sensitivity of 55% [41]. It is 
considered the best imaging modality for this evaluation.
4.4. Response assessment
[18F]FDG-PET/CT can also be used in response assessment 
3 months after completion of CCRT in combination with clin-
ical exam and MRI. MRI interpretation can be difficult due to 
the presence of post-therapy inflammation or scarring, 
although the addition of functional MRI sequences can be 
useful. Several authors showed that metabolic response was 
predictive of long-term survival. Nevertheless, attention 
should be given to interpretation of the partial metabolic 
response due to its high false-positive rate. In conclusion, 
[18F]FDG-PET/CT 3 months post-treatment has higher negative 
predictive than positive predictive values [42–44]. It appears 
that the most accurate post-treatment response assessment 
remains multimodal and associates a clinical evaluation with 
the pelvic MRI and the [18F]FDG-PET/CT .
5. Treatment phases
Major advances have occurred in the treatment of LACC over 
the past two decades, including the emergence of the crucial 
role of imaging in RT planning with the implementation of 
conformal techniques, such as intensity-modulated radiation 
therapy (IMRT)/volumetric arc therapy (VMAT), image-guided 
radiation therapy (IGRT) and image-guided adaptive bra-
chytherapy (IGABT), sparing the organs at risk (OAR) and con-
centrating the therapeutic dose to the primary disease. 
Furthermore, the addition of chemotherapy (CT) to RT has 
resulted in a significant improvement in local, regional and 
distant control rates.
5.1. Radiotherapy
5.1.1. External-beam radiotherapy (EBRT)
During the last few decades, significant evolutions in EBRT 
technology have occurred, moving from three-dimensional 
conformal radiation therapy (3D-CRT) to IMRT/VMAT and 
IGRT. With these improvements, survival has increased, and 
treatment-related morbidity has decreased [45]. IMRT allows 
more conformal shaping of RT dose to a specified target, with 
reduced high-dose exposure to surrounding OAR. A meta- 
analysis on 1008 patients with LACC found equivalent 3-year 
OS (Odds ratio (OR) 2.41, 95% CI 0.62–9.39, p = 0.21) and 
disease-free survival (DFS) (OR 2.41, 95% CI 0.62–9.39, 
p = 0.21) with IMRT and conventional RT but reduced acute 
toxicities [46]. On the other hand, Lin et al. [47] demonstrated 
that IMRT plus IGABT was associated with improved 5-year OS 
compared to patients treated with two-dimensional (2D)-RT 
and BT (61% versus 57%; p = 0.04). Furthermore, decreased 
grade 3–4 late bowel and bladder toxicities (18% vs 11%; 
p = 0.02) were observed [47].
A further benefit of IMRT is the opportunity to provide an 
additional 10–15 Gy dose to involved pelvic LNs using sequen-
tial or increasingly simultaneous integrated boost (SIB) 
techniques.
In a shorter treatment delivery time, VMAT allows reduction 
of the dose to the small bowel relative to IMRT, while doses to 
other OARs were comparable [48].
Furthermore, IGRT (by compensating for patient position-
ing errors and anatomical variations) is strongly recommended 
for reducing the dose to normal tissue and to ensure full dose 
coverage to the residual tumor upon completion of EBRT.
5.1.2. Brachytherapy (BT)
2D-based BT has been gradually replaced by IGABT based on 
3D volumetric imaging. This adaptive target volume concept 
reflects tumor shrinkage at the end of CCRT, with a risk- 
adapted dose prescription to different clinical target volumes 
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[49]. Also, IGABT clearly improves local control rate (LCR) and 
decreases toxicities [50–52].
The EMBRACE I prospective study included 1416 patients 
and was based on pioneering technical and clinical experience 
of several European institutions. The RetroEMBRACE trial, 
based on 814 patients, reported that 3-year local and pelvic 
control rates reached 98–100% and 96% for FIGO stage IB1 
and IB2 disease, respectively, and 93–96% and 89–91%, 
respectively, for stage IIB disease [52,53]. Stage III/IVA disease 
results were more variable, ranging from 73% to 86%. This 
improved local and pelvic control was associated with an OS 
benefit of approximately 10% compared to historical cohorts. 
Overall major morbidity (grades 3 to 5) was limited after IGABT 
(3 to 6% per organ) (10% and < 6% in grades III and IV late 
toxicities, respectively) [53–55]. EMBRACE II is an ongoing 
multicenter study initiated in April 2016 that is prospectively 
validating the findings of the both previous studies [56].
A Cochrane review confirmed that high-dose rate (HDR) 
and low-dose rate (LDR) irradiation are associated with similar 
survival and late toxicity. However, patients are increasingly 
treated by HDR irradiation because it allows outpatient BT 
application [57].
Overall treatment time (OTT) should be less than 50 to 
55 days. Indeed, a significant detrimental effect was well- 
described with a consistent loss of local control probability 
of approximately 1% per day of treatment prolongation 
beyond thresholds between 7 and 8 weeks [58,59]. The use 
of IMRT or stereotaxic body radiation therapy (SBRT) as 
a substitute for BT is not recommended because population- 
based studies have shown worse CSS with IMRT/SBRT as 
opposed to BT [60,61].
5.2. Chemotherapy
5.2.1. Concomitant chemotherapy
Five phase III investigating CCRT using either cisplatin, 
5-fluoro-uracil (5-FU), or hydroxyurea demonstrated 
a reduction in the risk of local and distant recurrences in 
patients with LACC and in patients with high-risk criteria 
after hysterectomy [62–66]. In 1999, the National Cancer 
Institute issued an alert recommending that ‘concomitant (cis-
platin-based) chemoradiotherapy should be considered 
instead of radiotherapy alone in women with cervical cancer’.
5.2.1.1. Results of meta-analyses. In 2008, a meta-analysis 
including 13 studies comparing CCRT to RT demonstrated an 
absolute benefit of 6% in 5-year OS (from 60 to 66%; Hazard 
ratio (HR) 0.81, 95% CI 0.71–0.9, p < 0.001) for the entire 
population but a decreased benefit with increasing stage. 
Acute toxicities were more frequent in the CCRT group, but 
few trials have evaluated late toxicity and quality of life (QoL) 
outcomes. However, interpretation of the real benefits were 
complicated by the use of different treatments in the control 
arms and by inconsistencies in patient outcomes [67]. In 2010, 
the Cochrane review reported that CCRT improved OS and PFS 
whether platinum or other chemosensitizing agents were used 
with absolute benefits of 10% (HR 0.83, p = 0.017) and 13% 
(HR 0.77, p = 0.009), respectively [68]. Datta et al. [69] per-
formed another meta-analysis in 2017 based on 2445 patients 
with > 95% SCC histology receiving either CCRT or RT only 
without surgery. The results confirmed that CCRT significantly 
improves outcomes, with increased LCR and OS rates of 8.4% 
(p < 0.001) and 7.5% (p < 0.001), respectively. This analysis also 
described a 10.4% (p < 0.001) higher incidence in grade III/IV 
acute toxicities, with an equivalent occurrence of late toxici-
ties. There were no differences in outcomes between weekly 
or 3-weekly cisplatin regimens [69].
Importantly, placement of CT has been poorly documented 
in the era of IGABT, as meta-analyses on the benefit of CT were 
conducted without image-guided or dose escalation 
techniques.
5.2.1.2. Impact of number of cycles of chemotherapy. In 
a retrospective trial including 189 patients (with stages III or 
IVA or with any stage who are also LN positive), Schmid et al. 
[70] showed a decreased in the distant metastasis-free survival 
(DMFS) with a decreased number of CT cycles (fewer than 5 
cycles) [70]. The EMBRACE I trial confirmed these results [56]. 
Recently, Escande et al. [71] demonstrated that patients 
receiving 5 cycles of concomitant CT experienced better out-
comes than those receiving only 4 cycles in terms of meta-
static (3-year DMFS = 56.3% vs 81.9%; HR 0.35, 95% CI 
0.21–0.57) and both local (3-year LC = 77.2% vs 93.9%; HR 
0.31, 95% CI 0.14–0.68) and regional control (3-year 
LRC = 62.8% vs 84.6%; HR 0.43, 95% CI 0.24–0.76) [71].
5.2.1.3. Monotherapy versus combination chemotherapy. 
Petrelli et al. [72] conducted a meta-analysis on 1500 patients, 
revealing that CCRT with cisplatin-based doublets significantly 
improved OS (OR 0.65; 95% CI 0.51–0.81; p = 0.0002), PFS (OR 
0.71; 95% CI 0.55–0.91; p = 0.006), and the rate of locoregional 
relapse (OR 0.64; 95% CI 0.47–0.89; p = 0.008) compared to 
CCRT with weekly cisplatin alone. However, higher toxicities 
were reported in the doublets group [72]. Another meta- 
analysis published by Ma et al. [73], on 1503 patients, showed 
that CCRT with platinum-based doublets significantly 
improved OS (HR 0.75; 95% CI 0.60–0.94; p = 0.01) and PFS 
(HR 0.78; 95% CI 0.65–0.94; p = 0.01) compared to CCRT with 
cisplatin monotherapy but was also accompanied by 
increased toxicities [73]. In conclusion, CCRT with a cisplatin- 
doublet seems to improve survival at the cost of inducing 
higher toxicity, which is probably why this concept is not 
adopted in daily practice.
5.2.1.4. Platinum versus non-platinum-based chemother-
apy. In the Vale et al. [67] and Cochrane meta-analyses, 
a survival benefit was observed for both groups of trials 
using platinum and non-platinum-based CCRT [67,68]. 
Nevertheless, no trials allowing a direct comparison have 
been published.
5.2.1.5. Weekly versus tri-weekly cisplatin schedule. In 
2020, a meta-analysis demonstrated that weekly cisplatin 
was associated with a higher incidence of local recurrence 
(OR 1.72; 95% CI 1.07–2.78; p = 0.03) and RT completion 
while lower risk of hematological toxicity. No significant differ-
ences were observed in terms of survival or acute adverse 
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effects [74]. The results of the phase III TACO trial are eagerly 
anticipated.
5.2.1.6. Place of carboplatin. No phase III randomized stu-
dies have compared carboplatin to cisplatin during CCRT. The 
use of carboplatin is supported by small phase I and II studies 
and pre-clinical evidence of synergism of this drug with RT 
[75]. A meta-analysis of 12 studies and 1698 patients sug-
gested poorer complete response (OR 0.53; 95% CI 0.34–0.82) 
and a trend toward inferior survival (3-year OS = OR 0.70; 95% 
CI 0.46–1.05) with weekly carboplatin [76].
5.2.2. Adjuvant chemotherapy
The role of adjuvant CT after CCRT has been explored in 
several phase II studies, showing an increased response rate 
[77–79]. Nevertheless, 4 phase III RCTs reported conflicting 
evidence (Table 1). In 2003, 926 patients were randomized 
into four arms: conventional RT; conventional RT plus adjuvant 
CT; conventional RT plus CCRT and conventional RT plus CCRT 
and adjuvant CT. CT consisted of intravenous mitomycin C and 
oral 5-FU. The pattern of failure revealed a significant increase 
in locoregional recurrence in the non-CCRT arm. On the other 
hand, metastatic rates were not significantly different. Five- 
year DFS was 48.2%, 54.1%, 64.5% and 59.7% for arms 1, 2, 3 
and 4, respectively [80].
Another randomized study on 515 patients compared CCRT 
with cisplatin and gemcitabine followed by two cycles of 
adjuvant cisplatin and gemcitabine, and conventional CCRT. 
They showed that PFS (HR 0.68, 95% CI 0.49–0.95, p = 0.023) 
and OS (HR 0.68; 95% CI 0.49–0.93, p = 0.022) at 3 years were 
both significantly improved in the gemcitabine arm. There was 
an increased benefit in patients with stages III–IVA. However, 
there was also an increased occurrence of grade 3–4 hemato-
logic toxicities and diarrhea (86.5% vs 45.3%, p < 0.001) 
[81,82]. A Cochrane review based on these 2 trials concluded 
that there are insufficient data and a need for further RCTs to 
definitively test the utility of adjuvant CT in this context [83]. 
Tang et al. [84] evaluated the addition of one cycle of cisplatin 
and paclitaxel prior and two cycles after CCRT in patients with 
ADC histology. Patients who received adjuvant CT exhibited 
significantly longer DFS (60.4% vs 71.4%, p < 0.05), less local 
relapse (62.9% vs 74.7%; p < 0.005) and distant metastases 
(p < 0.005) [84]. Fourthly, the ACTLACC trial randomized 259 
patients to receive CCRT with weekly cisplatin or adjuvant CT 
with paclitaxel plus carboplatin for 3 cycles followed by obser-
vation. There was no significant difference in PFS, OS or loco- 
regional failure. However, systemic recurrences were signifi-
cantly reduced in the adjuvant CT arm (8.4% vs 10.1%, 
p = 0.029), but only 75% of patients in the adjuvant CT arm 
completed the planned 3 cycles of CT with the trial being 
stopped early due to futility [85]. Despite the survival benefit 
reported in some of these trials, adjuvant CT is still not con-
sidered as a standard of care, mostly due to statistical flaws, 
excessive toxicity of some experimental treatments and inclu-
sion of only patients with ADC histology in one study. The 
phase III OUTBACK trial achieved its full recruitment and the 
results are eagerly awaited.
5.2.3. Neo-adjuvant chemotherapy (NACT)
The data concerning NACT were based on limited RCTs, with 
very heterogeneous inclusion criteria. Indeed, the design of all 
trials was different with respect to NACT before surgery, RT or 
CCRT, including many types of comparative arms, such as 
Table 1. Adjuvant chemotherapy trials.
LORVIDHAYA ET AL. [80] DUENAS-GONZALEZ ET AL. [81,82] TANG ET AL. [84] TANGJITGAMOL ET AL. [85]
Years of enrollment 1988–1994 2002–2004 1998–2007 2015–2017
Number of patients 926 515 880 259
Stage (FIGO) IIB to IVA IIB to IVA IIB to IVA IIB to IVA
Other criteria Stage IIB: only central tumor > 
3 cm and/or half of the 
parametrium involved
Patients with positive PAo LN 
(1> cm) from imaging must be 
negative in biopsy
Patients with positive PAo LN 
from imaging received 
extended-field RT
Patients with PAo 
enlargement from 
imaging are excluded
Histology SCC-ADC SCC-ADC-ADSC and poorly 
differentiated
ADC-ADSC SCC-ADC-ADSC
CCRT phase mitomycine C + oral 5-FU CCRT arm = cisplatin 
ACT arm = cisplatin + gemcitabine
cisplatin cisplatin
ACT phase oral 5-FU (3 cycles) cisplatin + gemcitabine (2 cycles) cisplatin + paclitaxel (2 cycles) + 
1 cycle before CCRT
carboplatin + paclitaxel (3 
cycles)
Median follow-up 89 months 46.9 months 60 months 27.4 months
Survival outcomes DFS at 5 years = better only in 
CCRT arm 
OS = NS
PFS and OS = 
in favor of ACT arm
DFS = in favor of ACT arm 3-year PFS = NS 
3-year OS = NS
Local relapse Significantly higher in non-CCRT 
arms
NS in favor of ACT arm NS
Distant relapse NS lower in ACT arm in favor of ACT arm lower in ACT arm
Toxicity increased in CCRT arm grade 3–4 more frequent in ACT arm leukopenia and 
thrombocytopenia significantly 
higher in ACT arm
grade 3–4 neutropenia 
higher in ACT arm
ACT = adjuvant chemotherapy; ADSC = adenosquamous carcinoma; ADC = adenocarcinoma; CCRT = concomitant chemoradiotherapy; DFS = disease-free survival; 
FIGO = International Federation of Gynecology and Obstetrics; 5-FU = 5-fluoro-uracil; LN = lymph node; NACT = neo-adjuvant chemotherapy; NS = not significant; 
OS = overall survival; PAo = para-aortic; PFS = progression-free survival; RT = radiotherapy; SCC = squamous cell carcinoma 
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surgery, RT or CCRT [86]. Therefore, the major obstacle is the 
adage of comparing ‘apples and oranges’.
5.2.3.1. NACT followed by surgery versus surgery 
(Table 2) 
.A 2012 Cochrane meta-analysis involving 1078 patients 
reported that patients treated with NACT followed by sur-
gery showed significantly better PFS (HR 0.75, 95% CI 0.61–-
0.93, p = 0.008) and OS (HR 0.77, 95% CI 0.62–0.96, p = 0.02) 
compared to those receiving surgery alone [87]. Another 
meta-analysis performed by Kim et al. [88] in 2013 reported 
that NACT followed by surgery reduced the need for adju-
vant RT according to risk factors (lymphovascular space 
invasion, deep stromal invasion, parametrial invasion, LN 
metastasis, and positive resection margins). However, NACT 
did not significantly improve OS or PFS. In observational 
studies subanalysis, OS was poorer in NACT arm (HR 1.68, 
95% CI 1.12–2.53) [88]. More recently, Zhao et al. [89], on 
2158 patients, demonstrated no differences in terms of OS, 
PFS, local or distant recurrences. In contrast, a subgroup 
analysis of patients with stage IB2-IIB showed that NACT 
followed by surgery significantly improved OS (OR 1.44, 
95% CI 1.01–2.05, p = 0.05), decreasing the local and distant 
(OR 0.43, 95% CI 0.25–0.73, p = 0.002) recurrence rates, LN 
metastasis rate, and levels of parametrial infiltration [89].
Nevertheless, due to the high rate of adjuvant RT after 
surgery alone in LACC, the standard used in these studies 
should no longer be surgery alone but rather, CCRT. 
Consequently, the control arm is obsolete, and the results of 
these meta-analyses are outdated.
5.2.3.2. NACT followed by surgery versus RT alone. A 
meta-analysis by Tierney et al. [90] involving 872 patients 
with stage IB – IVA revealed a 35% decrease in the risk of 
death (HR 0.65, p = 0.0004) in patients who received NACT 
followed by surgery compared to those who received RT 
alone, with an absolute improvement of 14% (from 50 to 
64%) in the 5-year OS rate [90]. Once more, RT without con-
comitant CT has become an obsolete standard, and the CT 
regimens used in these studies were not contemporary.
5.2.3.3. NACT followed by surgery versus CCRT (Table 3). 
The results of two phase III RCTs are currently available to 
address this issue. Gupta et al. [91] studied 635 patients with 
stages IB2, IIA, and IIB and compared NACT (3 cycles of carbo-
platin+ paclitaxel) followed by surgery to platinum-based 
CCRT. The primary endpoint was DFS. The authors found 
that 5-year DFS was lower (69.3% vs 76.7%; HR 1.38, 95% CI 
1.02–1.87, p = 0.038) in the NACT followed by surgery group 
with no significant differences in 5-year OS (75.4% vs 74.7%; 
HR 1.02, 95% CI 0.75–1.40, p = 0.87). Adverse events (AEs) at 
90 days were higher in CCRT arm: rectal (5.7% vs 13.3%; 
p = 0.002); bladder (2.8% vs 7.3%; p = 0.017) and vaginal 
(19.9% vs 36.9%; p < 0.001) toxicities, respectively. AEs at 
24 months were higher in CCRT arm but only for vaginal 
toxicity (12% vs 25.6%; p < 0.001).
Unfortunately, because of a slower-than-anticipated 
accrual over a 10-year period, the study was closed at 87% 
of the planned sample size [91]. Additionally, a trial led by 
the European Organization for Research and Treatment of 
Cancer (EORTC55994), including 626 patients with 
stages IB2-IIA2-IIB, was reported by Kenter et al. [92] during 
ASCO 2019 (not yet published). In intention-to-treat (ITT), an 
advantage of the CCRT arm in terms of PFS (56.7% vs 65.6%, 
p = 0.011) but not in OS (71.7% vs 75.6%, p = 0.253) was 
demonstrated but was not confirmed in patients who com-
pleted the total treatment. This trial reported a trend 
towards better results for CCRT in stage IIB (OS = 68% vs 
76%; HR 1.32, 95% CI 0.93–1.88), BMI < 25 and age > 
50 years, as well as a trend towards better results in NACT 
Table 2. Neo-adjuvant chemotherapy followed by surgery versus surgery.
RYDZEWSKA ET AL. [87] KIM ET AL. [88] ZHAO ET AL. [89]
Years of enrollment 1987–2005 1987–2010 1997–2016
Number of trials 6 RCTs 5 RCTs + 4 observational 13 studies
Number of patients 1078 1784 2158
Stage (FIGO) IB to IIIB IB1 to IIA IB to IIB
Histology SCC-ADC-ADSC SCC-ADC-ADSC SCC-ADC-ADSC
NACT phase cisplatin-based CT + vincristine/ 
bleomycin/5-FU or mitomycin C
cisplatin or carboplatin – based CT + vincristine/bleomycin/ 
5-FU/mitomycin C or paclitaxel
various regimens
Surgery type III Piver radical HT 
-pelvic lymphaD (3 trials) 
-pelvic + PAo lymphaD (2 trials)
type II or IV HT 
-pelvic lymphaD (all trials) 
-PAo lymphaD (if need)
radical HT 
-lymphaD = NE
Survival outcomes PFS and OS = in favor of NACT arm PFS = NS 
OS = NS 
OS (observational trials) = poorer in NACT arm
PFS and OS = NS 
-sub-analysis (IB2-IIB) 
PFS = NS 
OS = better in NACT arm
Local Relapse NS NS NS 
-sub-analysis (IB2-IIB) 
= decreased in NACT arm
Distant relapse NS decreased in NACT arm NS 
-sub-analysis (IB2-IIB) 
= decreased in NACT arm
ADC = adenocarcinoma; ADSC = adenosquamous carcinoma; CT = chemotherapy; FIGO = International Federation of Gynecology and Obstetrics; 5-FU = 5-fluoro- 
uracil; HT = hysterectomy; lymphaD = lymphadenectomy; NACT = neo-adjuvant chemotherapy; NE = not evaluated; NS = not significant; OS = overall survival; 
PAo = para-aortic; PFS = progression-free survival; RCTs = randomized controlled trials; SCC = squamous cell carcinoma 
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for combination CT. Concerning toxicity, treatment period 
grade 3–4 (gastro-intestinal and hematologic) was higher in 
the NACT arm (40.8% vs 22.6%), but follow-up period toxi-
city (gastro-intestinal and genito-urinary) was higher in the 
CCRT arm (15% vs 20.7%).
In the NACT group, 24% of patients received no surgery 
due to CT toxicity (34%), progression (24%) or insufficient 
response (16%). In the CCRT arm, only 6% of patients received 
no CCRT due to refusal (55%). In terms of response in the 
NACT group, 23% complete response, 15% ‘optimal’ response 
and 52% suboptimal response was observed [92]. Both trials 
had a similar study design and globally equal results. However, 
several points were different, such as primary outcome (OS or 
DFS), stages (inclusion of IIA1 or not) and histology (only SCC 
or mixed). Regarding treatment-related complications, short- 
term hematologic complications were significantly more fre-
quent in the NACT followed by surgery group than in the 
CCRT group. In contrast, long-term complications, such as 
small bowel and vaginal toxicities, were more frequent in the 
CCRT group. Together, these findings suggest that the stan-
dard of care for patients with LACC should remain definitive 
CCRT.
5.2.3.4. NACT followed by CCRT versus CCRT. In 2016, 
a review on 323 patients was conducted to evaluate NACT 
followed by CCRT. Due to limited data, the authors were 
unable to investigate the benefit of OS or PFS; however, they 
could determine the grade 3–4 toxicity rate (25%) and the 
response rate (70%). The most frequent grade 3–4 toxicity was 
neutropenia, followed by anemia, and then diarrhea [93]. The 
phase III INTERLACE trial is ongoing.
5.3. New agents
Even with current optimal treatment, recurrence rates remain 
high among patients with LACC, with only 65-70% of patients 
remaining disease-free long term. These unsatisfactory results 
have encouraged physicians to explore other novel strategies 
combined with the standard treatment [94]. Inhibition of 
angiogenesis by bevacizumab, a humanized anti-VEGF mono-
clonal antibody, has been found to have major activity in the 
metastatic CC setting [95]. In a phase II study, patients with 
stage IB to IIIB were treated with weekly cisplatin during CCRT 
followed by BT. Patients also received 3 cycles of bevacizumab 
during CCRT. The regimen was well tolerated, with grades 3 
and 4 toxicity of 26.5% and 10.2%, respectively. OS, DFS, and 
local relapse-free rate at 3 years were 81.3%, 68.7%, and 
23.2%, respectively [96].
Another approach involves using immune checkpoint 
receptors inhibitors, such as anti-programmed cell death/cell 
death ligand (PD-1/PD-L1) and anti-cytotoxic T lymphocyte- 
associated antigen 4 (CTLA-4). Currently, data are increasingly 
available regarding utilization of these molecules in the meta-
static setting [97]. CCRT in combination with checkpoint 
Table 3. Neo-adjuvant chemotherapy followed by surgery versus concomitant chemoradiation.
GUPTA ET AL. [91] KENTER ET AL. [92]
Years of enrollment 2003–2015 2002–2014
Number of patients 635 626
Stage (FIGO 1994) IB2-IIA or IIB IB2-IIA2-IIB
Histology SCC SCC-ADC-ADSC
First endpoint DFS OS at 5 years
Median follow-up 58.5 months 96 months
NACT phase carboplatin + paclitaxel (3 cycles) -cisplatin monotherapy (dose at least 225 mg/m2) (46%) 
-doublet (+ paclitaxel) (20%) 
-triplet (+ paclitaxel + ifosfamide) (19%) 
-other (15%)
CCRT phase -EBRT 40 Gy (20 x 2 Gy) 
+ ICBT (LDR 2 × 30 Gy or HDR 5 × 7 Gy) 
-CT = cisplatin weekly
-EBRT 45–50 Gy (pelvis) 
with external boost or BT 
-CT = cisplatin weekly
Adjuvant treatment after 
protocol completion
*in NACT arm, 
-21.5% crossover to CCRT (pre-surgery and 
intraoperative unresectable disease) 
-13.3% = adjuvant CCRT 
-9.8% = adjuvant RT alone
*in NACT arm, 
-24% = no surgery (34% CT toxicity; 24% progressive; 16% insufficient 
response; 14% patient refused) 
-14% = adjuvant RT 
*in CCRT arm, 
-6% = no CCRT (55% patient refused; 25% protocol violation, . . .) 
-4% = surgery
Survival outcomes 5 year PFS = in favor of CCRT 
5 year OS = NS
OS (ITT and completed treatment) = NS 
PFS (ITT) = in favor of NACT arm 
PFS (completed treatment) = NS
Survival sub-analysis *stages IB2 or IIA: 
DFS = NS
*stage IB2: 
OS = trend in favor of NACT arm 
*stage IIB: 
OS = trend in favor of CCRT arm
Toxicity -grade 3–4 thrombocytopenia = higher in NACT arm 
-grade 3–4 bladder and GI = NS 
-AEs at 90 days, higher in CCRT arm (rectal, bladder 
and vaginal) 
-AEs at 24 months, higher in CCRT arm (only vaginal)
-treatment period grade 3–4: higher in NACT arm (GI and hematologic) 
-follow-up period grade 3–4: higher in CCRT arm (GI and GU)
ADC = adenocarcinoma; ADSC = adenosquamous carcinoma; AEs = adverse events; BT = brachytherapy; CCRT = concomitant chemoradiotherapy; 
CT = chemotherapy; DFS = disease-free survival; EBRT = external-beam radiotherapy; FIGO = International Federation of Gynecology and Obstetrics; GI = gastro- 
intestinal; GU = genito-urinary; HDR = high-dose rate; IC = intra-cavitary; ITT = intention-to-treat; LDR = low-dose rate; NACT = neo-adjuvant chemotherapy; 
NS = not significant; OS = overall survival; PFS = progression-free survival; RT = radiotherapy; SCC = squamous cell carcinoma 
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inhibitors may induce an increased immunogenic environ-
ment by initiating DNA breaks, cell death, and antigen pre-
sentation, leading to enhancing anti-tumor activity. Moreover, 
CC itself is a highly immunogenic disease due to chronic HPV 
infection. Indeed, in the presence of chronic HPV infection, 
a natural immune response develops with activation of the 
adaptive immune system. Of note, PD-L1 expression increases 
with higher grades cervical intra-epithelial neoplasia, and 88% 
LACC cases exhibit ≥ 1% positive PD-L1 [98]. Several trials with 
CTLA-4 (ipilimumab), PD-1 (pembrolizumab, nivolumab) or PD- 
L1 (durvalumab and atezolizumab) checkpoint inhibitors are 
ongoing in the LACC setting [97,99].
Therapeutic live vaccines targeting HPV have also been 
developed using bacterial vectors from a variety of bacterial 
species [97,100]. Adoptive cell therapy with tumor-infiltrating 
lymphocytes, activated and expanded ex vivo is another 
potential strategy [101,102].
Finally, triapine, a ribonucleotide reductase inhibitor, 
showed preliminary interesting results in a phase II trial, in 




Most of our knowledge on the treatment of CC comes from 
studies in which the majority of patients had SCC. Moreover, 
no RCTs are specifically dedicated to this histological subtype.
Compared to SCC, ADC appears to be associated with 
a worse prognosis, a greater distant metastases rate, 
a higher resistance to RT and less chemosensitivity [104–107]. 
However, there is no definitive information regarding the 
prognostic significance of ADC among patients with LACC 
treated with definitive RT or CCRT.
Despite the suggested differences, according to the inter-
national guidelines, current management of the ADC histolo-
gical subtype is similar to that of SCC in LACC.
6. Adjuvant hysterectomy (HT)
The evidence that systematic HT following CCRT improves 
survival in women with LACC is lacking. Moreover, due to RT- 
induced inflammation and vascular fibrosis, surgery has an 
increased risk of significant per- and post-operative complica-
tions, such as entero-vesical and vesico-vaginal fistulas. 
Residual disease (RD) after primary CCRT is directly associated 
with local recurrence, and optimal treatment of this situation 
remains unclear [51].
One of the primary limitations to adjuvant HT is that ima-
ging modalities cannot accurately predict RD. Classically, 
tumor response is assessed by clinical examination, pelvic 
MRI and [18F]FDG-PET/CT 3 months after completion of treat-
ment. Valduvieco et al. reported a 60% correlation between 
MRI and clinical findings at 3 months with a further increase of 
up to 80% at 6 months [108]. Vincens et al. [109] reported 
a false-positive rate of 50% between MRI and pathological 
findings. It seems that diffusion-weighted sequences could 
be useful [109]. Indeed, interpretation of pelvic MRI can be 
difficult due to the presence of radiation-induced 
inflammation or scarring. [18F]FDG-PET/CT can be helpful, but 
attention should be given to its interpretation due to 
its higher negative predictive than positive predictive values 
[42–44]. Very few and old data have been published concern-
ing the results of surgery after CCRT. Moreover, these publica-
tions are mixtures of different situations in terms of disease 
stage, dose and techniques of EBRT and CT schedules. 
Furthermore, variability was observed with respect to the 
type of surgical method and realization of lymphadenectomy 
or not. Consequently, there is major difficulty in interpreting 
these results. But, all these studies confirmed a higher rate of 
postoperative complications with similar outcomes 
[55,110–115].
However, it is important to underline the ‘recommenda-
tions’ of National Comprehensive Cancer Network (NCCN) 
guidelines. For stage IB3 or IIA2 tumors, their panel of experts 
had a major disagreement about recommending adjuvant HT 
(category 3) after primary CCRT [116]. Also, a Cochrane review 
analyzed whether the addition of HT to standard non-surgical 
treatments had a clear benefit for patients with LACC, in terms 
of local control and/or OS. The findings were considered 
insufficient to demonstrate a survival benefit associated with 
adjuvant HT [117]. The morbidity is higher after HT, but this 
could be decreased using a laparoscopic technique [64,118]. 
Although routine HT remains not recommended, this 
approach could potentially be considered in patients in 
whom the primary extent of disease or the anatomy of the 
uterus precludes an adequate coverage by BT [116].
7. Follow-up
Surveillance will ideally benefit patients with local relapse, 
offering potentially curative treatment. More than 75% of 
recurrences occur within the first 2–3 years after the initial 
treatment, suggesting a role for intensive surveillance during 
this period. Follow-up schedules may be individualized, taking 
into account prognostic factors, treatment modality and side 
effects. No prospective studies with direct comparisons of 
follow-up regimens have been published. The primary objec-
tive of surveillance is to provide a clinical and cost-effective 
approach for detecting recurrence and affecting survival out-
comes. International guidelines recommend follow-up evalua-
tion every 3–4 months for the first 2 years and every 6 months 
for the next 3 years. Patients should return to annual popula-
tion-based general physical and pelvic examinations after 
5 years [119]. Follow-up visits should include a complete phy-
sical examination, with a pelvic–rectal exam and a detailed 
patient history. In women treated with primary RT, the inci-
dence of an abnormal Pap test ranges from 6% to 34%, with 
atypical squamous cells of undetermined significance account-
ing for most of the abnormalities. Indeed, the value of Pap 
cytology in the detection of recurrence is very limited; more-
over, the results may represent artifacts in irradiated patients 
[120]. In patients with clinical suspicion of recurrence, [18F] 
FDG-PET/CT detected disease with both high sensitivity 
(86%) and specificity (87%). It only has a role in cases of 
suspected recurrence where MRI or CT imaging is equivocal. 
There is no definitive evidence supporting the routine use of 
8 C. GENNIGENS ET AL.
[18F]FDG-PET/CT in patient follow-up. Biopsy should always be 
obtained in case of doubt [10,121].
8. Sexual function after treatment
LACC is frequently diagnosed in women at a median age of 50. 
Thus, late sequelae related to treatment must be taken into 
consideration with a particular interest for their sexual func-
tion. Sexual morbidity is a complex issue, commonly due to 
physical and/or psychological impacts related to various 
tumor and treatment factors. Several retrospective studies 
concluded that sexual dysfunction is particularly common 
after RT for CC, although women treated with radical HT can 
also notice an alteration of their sexual function [122–124]. 
The impact of RT is mainly attributed to pelvic fibrosis, vaginal 
stenosis and decreased vaginal lubrication, resulting in dyspar-
eunia and sexual worries [125]. Based on the EMBRACE study, 
Kirchheiner et al. [126] described that 41.5% of patients 
reported no, 12.3% occasional and 46.3% frequent sexual 
activity after treatment. Before treatment, vaginal dryness, 
shortening, tightening and pain during intercourse were only 
reported by 7.1%, 2.9%, 4.8% and 10.5% of patients, respec-
tively. During follow-up (median 36 months), these side effects 
increased to 38.4%, 36.4%, 34.2% and 33.5%, respectively 
[126]. In younger women treated with RT, induction of pre-
mature menopause is systematic after EBRT. Indeed, RT 
directly damages the endocrine function of the ovaries. 
However, a systematic review in gynecological cancers (includ-
ing 93% of CC) found that ovarian transposition can preserve 
the ovarian function in 94% of women having BT and 65% of 
women undergoing both BT and EBRT [127]. It is also of 
utmost importance to develop efforts to prevent vaginal mor-
bidity and prospectively propose individualized sexual rehabi-
litation options after treatment such as menopause hormone 
remplacement therapy [128], vaginal dilatation, pelvic 
physiotherapy, . . .
9. Conclusions
Major progresses have been made in treating patients with 
LACC (FIGO 2018 stages IB3-IVA) during the past decades.
The updated 2018 FIGO classification uses imaging and 
pathological findings to designate the final stage of the dis-
ease. This new version has improved capacity to discriminate 
between the three subgroups of stage IB. Furthermore, inclu-
sion of LN status is a major change that more accurately 
reflects the prognosis. Nevertheless, survival remains hetero-
geneous among patients within stage III subgroups.
Imaging has assumed an increasingly important place in 
the initial workup and the post-treatment evaluation but also 
in RT planning. In the latter, imaging has allowed implementa-
tions of more conformal radiation techniques, such as IMRT/ 
VMAT, IGRT and IGABT. These new approaches in combination 
with concomitant CT clearly increase local control rates while 
also influencing OS and decreasing toxicities.
Cisplatin-based CCRT demonstrates survival benefit com-
pared to RT alone. Currently, the standard of care is con-
comitant cisplatin-based chemoradiation followed by IGABT 
with an OTT less than 55 days. Cisplatin at 40 mg/m2 per 
week is administered on the first or second day of each 
week of EBRT for 5 cycles. EBRT is typically administered at 
1.8 Gy/day five days per week for 25 days, delivering a total 
dose of 45 Gy to the entire pelvis. The primary tumor is 
subsequently boosted, using image-guided BT, with an addi-
tional 30 to 40 Gy for a total dose of 85 Gy. Bulky nodes are 
boosted with an additional 10 to 15 Gy focused on adeno-
pathy. In cases of positive PAo LN (evaluated by metabolic 
imaging and/or surgery), the RT field is extended to cover 
this region up to the level of the 10th dorsal vertebrae. In 
cases of initial parametrial invasion or major residual disease 
at the end of EBRT, interstitial BT techniques should be used 
to increase the dose delivered to the high-risk clinical target 
volume; this latter technique should be limited to institu-
tions with experience and expertise. Carboplatin (area under 
the curve two) may represent an alternative in patients 
considered unfit for cisplatin (Figure 1).
The precise role of neo- and adjuvant CT is still debated 
due to conflicting data. The results of major trials, such as 
INTERLACE and OUTBACK, are eagerly awaited.
Despite these significant advances, OS at 5 years remains 
around 65-70%, and the disease will recur in approximatively 
40% of patients. The prognosis is therefore still suboptimal, 
and new strategies trials are ongoing.
These trials are testing new drugs in combination with 
cisplatin-based CCRT continued in maintenance, such as anti-
angiogenesis agents, checkpoint immune receptors and RNR 
inhibitors. Adoptive T-cell therapy has also shown promising 
results in the metastatic setting and could be implemented in 
the context of LACC disease.
To perform a systematic hysterectomy after CCRT followed 
by IGBAT is not recommended due to having no proven 
benefits on survival and an accompanying high rate of mor-
bidities, particularly in the form of urinary fistulae. On the 
other hand, place of surgery in case of residual disease or 
local relapse is a debate not fully resolved. Individual decisions 
should be made for each patient in this situation. Concerning 
residual disease, the major problem remains how to identify 
patients who would most benefit from surgery.
The evidence concerning follow-up is currently lacking. At 
minimum, physical examination and clinical history should be 
performed by specialists with frequencies adapted to the risk 
of recurrence. Systematic cytological Pap test and imaging are 
not recommended.
10. Expert opinion
The optimal care of patients suffering from LACC begins 
with an exhaustive initial diagnostic workup performed by 
a multidisciplinary expert team. Indeed, this step deter-
mines and individualizes the entire treatment plan, which 
includes a thorough clinical and radiological examination. 
For selected patients, a surgical approach to obtain 
a definitive PAo LN status may be indicated. However, 
the best strategy for the detection of PAo LN status 
remains a controversial topic. The subgroup that tends to 
derive the most benefit of surgical approach is that of 
patients with positive pelvic nodes and negative PAo 
nodes on pre-therapeutic [18F]FDG-PET/CT. However, only 
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the results of a well-designed RCT will end this debate by 
clarifying the hypothetical survival benefit of such surgical 
staging.
Beyond this multidisciplinary initial workup, profiling the 
patient and tumor risks of relapse based on biomarkers is 
essential. Some have been proposed (tumor size, nodal 
Figure 1. Optimal treatment for LACC: step by step. AUC = area under the curve; EBRT = external-beam radiotherapy; [18F]FDG-PET/CT = 18F-2ʹ-deoxy-2ʹ 
fluorodeoxyglucose; HDR = high-dose rate; IGABT = image-guided adaptive brachytherapy; IGRT = image-guided radiotherapy; IMRT = intensity-modulated 
radiation therapy; LN = lymph node; MRI = magnetic resonance imagery; OTT = overall treatment time; PAo = para-aortic; PDR = pulsed-dose rate; 
RT = radiotherapy; 3D = three-dimensional; VMAT = volumetric arc therapy.
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status, histology, metabolic avidity, etc.) but are not satis-
factory. Molecular biomarkers are probably the key and 
could be used as predictive factors to help us select better 
patients for intensification of systematic therapy. Moreover, 
all of these molecular alterations are of potential clinical 
relevance, as a number of these proteins may represent 
targets for new drugs in the metastatic setting and could 
subsequently be tested in the initial treatment of LACC 
disease.
As far as definitive treatment is concerned, conformal RT 
techniques in combination with concomitant chemotherapy 
clearly improve local control rates and overall survival, while 
decreasing toxicities. It is likely that a ‘plateau’ curve has been 
reached concerning local control rate, except perhaps for very 
bulky tumors. In contrast, uncontrolled distant metastatic 
spread is still responsible for the majority of failures among 
patients with LACC. How can we better select patients with 
aggressive disease and tailor their treatment? The molecular 
characteristics described above must be explored for their 
capacity to discriminate between low- and high-risk patients. 
Furthermore, adenocarcinoma represents 20% of cases with 
a constantly rising incidence. Currently, LACC is treated inde-
pendently of the histological subtype, with data supporting 
reduced chemosensitivity for ADC, likely explained on 
a molecular basis.
Various therapeutic strategies, some still under investiga-
tion, have been proposed to improve the outcome of patients 
suffering from LACC: adding novel targeted agents with CT, 
using other CT schedules either alone or in combination with 
platinum, modifying the dose or CT regimen, neoadjuvant CT 
followed by surgery or CCRT, adjuvant CT, and, more recently, 
use of immunotherapeutic approaches. Nonetheless, no ther-
apeutic strategy has demonstrated a clear impact on patient 
outcome, although the key to improving the control of sub-
clinical micrometastases likely relies on systemic adjuvant 
therapy. The results of the well-designed OUTBACK and 
INTERLACE trials are eagerly anticipated. Post treatment sys-
tematic hysterectomy has also been unable to demonstrate an 
improved outcome but is linked to significant morbidity and 
should no longer be proposed (except in very specific 
situation).
Last but not least among the remaining challenges is to 
control treatment-related morbidity and to ensure QoL for 
patients. Patients treated with RT can develop vaginal 
stenosis and dryness and should receive education by 
expert team regarding sexual and vaginal issues. 
Furthermore, CC survivors are at risk for second cancers. 
Data suggest that patients receiving RT for pelvic cancers 
are at risk for radiation-induced secondary neoplasms, 
especially at irradiated sites near the cervix (colon, rec-
tum/anus, and bladder); careful surveillance is recom-
mended in these patients.
At the time of this review and after having witnessed major 
multidisciplinary efforts made to improve the outcome of 
patient suffering from LACC, it appears essential to recall 
that 85% of these neoplasms occur in developing countries 
where access to appropriate therapy is absent or suboptimal. 
Furthermore, national health systems should concentrate on 
optimizing their prevention program, which constitutes the 
most cost effective approach to reduce the incidence and 
mortality of cervical cancer.
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